GlaxoSmithKline taking pandemic vaccine orders

May 15, 2009

(AP) -- Pharmaceutical giant GlaxoSmithKline said Friday it has received orders from several countries to stockpile pandemic vaccine as soon as it gets the vaccine's key ingredient from the World Health Organization.

As the continues to spread worldwide - WHO says 34 countries have reported more than 7,500 cases - health officials are deciding when to ask vaccine makers to start making a vaccine to fight the virus.

"We expect this pattern of spread to continue," said Dr. Margaret Chan, WHO's director-general on Friday, before the U.N. health agency's yearly meeting of its 193 member states. According to WHO's pandemic alert scale, the world is currently in phase 5 of a possible 6, meaning a global flu outbreak is imminent.

About a dozen developed countries, including Canada, France and the United States, have struck advance deals with vaccine producers like PLC and Sanofi Aventis to provide pandemic vaccine as soon as their factories start producing it.

WHO will also ask vaccine producers to save a portion of their pandemic vaccines for poor nations.

A pandemic vaccine based on the swine flu virus could be available in four to six months, once companies receive the "seed stock" from WHO. That is currently being developed by the U.S. , and is expected to be ready in the next few weeks.

In a press statement, Glaxo said it had received "interest" from several governments keen to stock swine flu vaccine, including Britain, France, Belgium and Finland.

On Thursday, WHO convened a group of vaccine manufacturers and other experts to discuss issues such as when swine flu vaccine production should begin, how many doses will be needed and who should get the vaccines.

WHO flu chief Keiji Fukuda said there were no big decisions about swine flu vaccine and that more meetings would be needed before the agency made any recommendations to manufacturers.

Next week, WHO's Chan and U.N. Secretary-General Ban Ki-moon will meet with vaccine makers to discuss swine flu issues.

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: Early bottlenecks in developing biopharmaceutical products delay commercialization

add to favorites email to friend print save as pdf

Related Stories

WHO meets on production of swine flu vaccine

May 14, 2009

(AP) -- As swine flu cases hit 6,500 worldwide, World Health Organization officials were meeting with vaccine manufacturers and other experts in Geneva on Thursday to discuss making a vaccine to fight the virus.

US wants ingredient in swine flu vaccine by May

Apr 28, 2009

(AP) -- U.S. scientists hope to have a key ingredient for a swine flu vaccine ready in early May, but tell The Associated Press that the novel virus grows slowly in eggs - the chief way flu vaccines are made.

Possible seasonal shot seen for bird flu

May 04, 2006

A seasonal flu shot against a possible bird flu pandemic is reported to be under consideration by U.S. public health officials at a Singapore conference.

Unusual flu vaccine is developed

Jun 14, 2006

U.S. scientists have used reverse genetics to develop an influenza virus with two key proteins on its surface derived from the H5N1 avian virus strain.

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0